Elotuzumab + Bortezomib/Dexamethasone Provide Clinical Benefit to Pts With R/R Multiple Myeloma

Share this content:
Elotuzumab seemed to provide clinical benefit in patients with relapsed/refractory multiple myeloma.
Elotuzumab seemed to provide clinical benefit in patients with relapsed/refractory multiple myeloma.

Elotuzumab seemed to provide clinical benefit without clinically significant toxicity when combined with bortezomib/dexamethasone (Bd) vs Bd alone in patients with relapsed/refractory multiple myeloma, according to results of a phase 2 study published in Blood.1

In this proof-of-concept open-label study, patients received elotuzumab, an immunostimulatory antibody, with Bd or Bd alone until disease progression or unacceptable toxicity. Primary endpoint was progression-free survival; secondary endpoints included overall response rate and overall survival. Efficacy and safety analyses were also performed.

A total of 152 patients were included (77 received elotuzumab/Bd; 75 received Bd), 150 were treated (75 in the elotuzumab/Bd group; 75 in the Bd group).

Results showed that progression-free survival was greater with elotuzumab/Bd vs Bd (HR, 0.72; 70% CI: 0.59 – 0.88; stratified log-rank P = .09); median progression-free survival was longer as well, 9.7 months vs 6.9 months, respectively.

An updated analysis revealed that elotuzumab/Bd-treated patients homozygous for the high-affinity FcyRLLLa allele had a median progression-free survival of 22.3 months vs 9.8 in elotuzumab/Bd-treated patients homozygous for the low-affinity allele. Patients in the elotuzumab/Bd had an overall response rate of 66% vs 63%. Patients in the elotuzumab/Bd group had very good partial response or better rate of 36% vs those in the Bd group had 27%.

RELATED: Q&A With Dr Muhammad A. Mir: Allogeneic Stem Cell Transplantation for Multiple Myeloma

Early overall survival results, based on 40 deaths showed an HR of 0.61 (70% CI: 0.43 – 0.85). A total of 60 deaths have occurred so far (28 elotuzumab/Bd; 32 Bd).

No significant adverse events occurred with elotuzumab/Bd vs Bd. The rate of grade 1/2 infusion reactions was low (5% in the elotuzumab arm) and controlled with premedication.


  1. Jakubowiak A, Offidani M, Pegourie B, et al. Randomized phase 2 study of elotuzumab plus bortezomib/dexamethasone (Bd) versus BD for relapsed/refractory multiple myeloma [published online ahead of print April 18, 2016]. Blood. doi: 10.1182/blood-2016-01-694604.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs